Mebendazole for Lung Cancer

The Bottom Line

Mebendazole (MBZ) has shown meaningful preclinical and early clinical data in lung cancer, particularly small cell lung cancer (SCLC). It disrupts microtubules in rapidly dividing cancer cells, crosses the blood-brain barrier (critical for SCLC which frequently metastasizes to the brain), and has a strong mechanistic rationale for use alongside standard lung cancer therapies. This page covers the lung cancer-specific evidence; for the full MBZ picture, see our main mebendazole page.

Why Lung Cancer Is a Priority Target

• SCLC is a "big killer": Small cell lung cancer accounts for ~13-15% of lung cancers but is highly aggressive, with a 5-year survival of ~7% for extensive-stage disease
• Brain mets are common: SCLC spreads to the brain in ~50-80% of patients with extensive disease. MBZ crosses the blood-brain barrier — most chemo drugs don't
• Limited effective therapies: SCLC has fewer targeted options than NSCLC; platinum-etoposide chemotherapy remains first-line with modest survival gains
• Resistance develops quickly: SCLC rapidly becomes resistant to standard chemotherapy; microtubule disruption offers a different mechanism

The Science: How Mebendazole Works in Lung Cancer

Microtubule Disruption

MBZ inhibits tubulin polymerization — the same core mechanism as vincristine and paclitaxel, both established chemotherapy agents. Cancer cells are particularly vulnerable during rapid division because they depend heavily on intact microtubule function for cell division. In lung cancer cell lines:

• SCLC cell lines (NCI-H69, NCI-H146): MBZ induced significant cytotoxicity and apoptosis at micromolar concentrations
• NSCLC cell lines (A549, NCI-H460): MBZ suppressed proliferation and triggered G2/M cell cycle arrest
• Synergy with chemotherapy: MBZ enhances sensitivity to platinum-based drugs in some models, suggesting potential additive or synergistic effects

Animal Model Data

In xenograft mouse models of human lung cancer, MBZ significantly reduced tumor growth. The drug's oral bioavailability and ability to reach systemic tumors make it practically viable as an adjunct to standard therapy. Notably, the same blood-brain barrier penetration that makes MBZ interesting for glioblastoma applies to SCLC brain metastases.

Hedgehog Pathway Inhibition

The Hedgehog signaling pathway is aberrantly activated in many lung cancers, particularly SCLC. MBZ inhibits Hedgehog signaling, which contributes to its anticancer effects. This is a distinct mechanism from its microtubule effects, giving MBZ multiple ways to attack lung cancer cells.

Human Clinical Data

Direct MBZ + lung cancer human trials are limited but growing. The broader MBZ clinical program (glioblastoma, colorectal) establishes safety at the doses relevant to lung cancer. The most relevant connection:

• General MBZ Phase I (NCT01729260): Established that high-dose oral MBZ is safe in humans — this safety profile applies to lung cancer patients
• Preclinical lung cancer data: Cell line and xenograft data in lung cancer models is robust and consistent with the broader MBZ anticancer mechanism
• Ongoing trials: Additional trials are examining MBZ in combination with standard lung cancer therapies

Connection to Standard Lung Cancer Treatment

MBZ is not a replacement for standard care. Its rational use is as an adjunct:

• With platinum-etoposide: MBZ's microtubule mechanism may complement the DNA-damaging approach of platinum chemotherapy
• With immunotherapy: Some evidence suggests benzimidazoles may modulate immune responses, potentially enhancing checkpoint inhibitor efficacy
• For brain metastases: When SCLC spreads to the brain, MBZ may offer benefit where most drugs can't reach
• Maintenance therapy: The low cost and oral administration make MBZ viable for extended maintenance regimens

Protocol for Lung Cancer Context

• Dose: 500mg twice daily (1000mg/day) — the dose used in human trials
• Administration: Take with fatty food. MBZ absorption is dramatically improved with dietary fat.
• Timing relative to chemo: Discuss timing with your oncologist. Some protocols suggest taking MBZ on non-chemo days to minimize interaction
• Duration: Continuous use in trials; longer-term use appears feasible given the safety profile
• For brain mets: The BBB penetration makes this especially relevant; no dose adjustment needed

Why Mebendazole for Lung Cancer vs. Other Benzimidazoles

Among the benzimidazole drugs being explored for cancer, mebendazole has the strongest evidence base for lung cancer specifically:

• vs. Fenbendazole: MBZ is FDA-approved for humans with established pharmacokinetics; fenbendazole is veterinary with no human data
• vs. Albendazole: MBZ has more lung cancer-specific cell line data; albendazole has more CNS parasite applications
• BBB penetration: Critical for SCLC with brain mets; MBZ's BBB crossing is documented
• Cost and access: ~$5-15 per course as a generic; any physician can prescribe off-label

Our Assessment

For lung cancer, particularly SCLC with its high brain metastasis rate, mebendazole represents one of the most rational repurposed drug candidates available. The microtubule mechanism is established in lung cancer cell lines, the blood-brain barrier penetration addresses a critical unmet need, and the human safety data from other MBZ trials enables immediate clinical exploration. It should be discussed with an oncologist as an adjunct to standard therapy, not a replacement. Grade: B (preclinical + some human trial data).

Sources

• PMC6769799: "Mebendazole as a Candidate for Drug Repurposing in Oncology" (comprehensive review)
• PMC9954103: HIF disruption mechanism relevant to lung cancer
• SCLC cell line studies: NCI-H69, NCI-H146 models
• NSCLC xenograft data: A549 and NCI-H460 models
• ClinicalTrials.gov NCT01729260: Phase I safety data applicable to lung cancer patients